{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:51:54Z","timestamp":1791219114130,"version":"4.1.0"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2018,7,27]],"date-time":"2018-07-27T00:00:00Z","timestamp":1532649600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:p>\n                    Cryptococcal meningitis (CM), caused primarily by\n                    <jats:named-content content-type=\"genus-species\">Cryptococcus neoformans<\/jats:named-content>\n                    , is uniformly fatal if not treated. Treatment options are limited, especially in resource-poor geographical regions, and mortality rates remain high despite current therapies.\n                  <\/jats:p>","DOI":"10.1128\/aac.00523-18","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T05:35:41Z","timestamp":1528349741000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":120,"title":["<i>In Vitro<\/i>\n                    and\n                    <i>In Vivo<\/i>\n                    Evaluation of APX001A\/APX001 and Other Gwt1 Inhibitors against Cryptococcus"],"prefix":"10.1128","volume":"62","author":[{"given":"Karen Joy","family":"Shaw","sequence":"first","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiley A.","family":"Schell","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Covel","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele","family":"Duboc","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Giamberardino","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mili","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Molly","family":"Moloney","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quinlyn A.","family":"Soltow","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Tenor","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena L.","family":"Toffaletti","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Trzoss","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Webb","sequence":"additional","affiliation":[{"name":"Amplyx Pharmaceuticals, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Perfect","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e328322ffac"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30243-8"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/649858"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1710922"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1086\/518607"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110404"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01800-12"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0043582"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.000656"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S38850"},{"key":"e_1_3_3_12_2","volume-title":"Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability, poster 1860","author":"Hodges MR","year":"2017","unstructured":"Hodges MR, Ople E, Shaw KJ, Mansbach RS, van Marle S, van Hoogdalem E, Kramer W, Wedel P. 2017. Phase 1 study to assess safety, tolerability and pharmacokinetics of single and multiple oral doses of APX001 and to investigate the effect of food on APX001 bioavailability, poster 1860. Abstr IDWeek 2017, San Diego, CA."},{"key":"e_1_3_3_13_2","volume-title":"First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects, poster 1840","author":"Hodges MR","year":"2017","unstructured":"Hodges MR, Ople E, Shaw KJ, Mansbach RS, van Marle S, van Hoogdalem E, Wedel P, Kramer W. 2017. First-in-human study to assess safety, tolerability and pharmacokinetics of APX001 administered by intravenous infusion to healthy subjects, poster 1840. Abstr IDWeek 2017, San Diego, CA."},{"key":"e_1_3_3_14_2","volume-title":"In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377","author":"Hata K","year":"2011","unstructured":"Hata K, Horii T, Miyazaki M, Watanabe NA. 2011. In vitro and in vivo antifungal activities of E1211, a water-soluble prodrug of E1210, abstr F1-1377. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2003.03481.x"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M301044200"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00731-11"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1021\/cb300235m"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05414-11"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00291-11"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-11"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2011.05.001"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr342"},{"key":"e_1_3_3_24_2","volume-title":"APX001 is effective against echinocandin and multi-drug resistant Candida isolates","author":"Zhao Y","year":"2018","unstructured":"Zhao Y, Lee M, Lee A, Paderu P, Park S, Perlin DS. 2018. APX001 is effective against echinocandin and multi-drug resistant Candida isolates. Abstr 28th ECCMID, Madrid, Spain."},{"key":"e_1_3_3_25_2","volume-title":"In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378","author":"Watanabe NA","year":"2011","unstructured":"Watanabe NA, Horii T, Miyazaki M, Hata K. 2011. In vitro activity of E1210 and in vivo activity of E1211, a water-soluble prodrug of E1210, in combination with other antifungals, abstr F1-1378. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_3_26_2","volume-title":"APX001 protects immunosuppressed mice from Rhizopus delemar infection, poster 1521","author":"Gebremariam T","year":"2017","unstructured":"Gebremariam T, Alkhazraji S, Alqarihi A, Wiederhold NP, Shaw KJ, Patterson TF, Filler SG, Ibrahim A. 2017. APX001 protects immunosuppressed mice from Rhizopus delemar infection, poster 1521. Abstr IDWeek 2017, San Diego, CA."},{"key":"e_1_3_3_27_2","volume-title":"Efficacy of oral APX001 in a murine model of cryptococcal meningitis, poster 1529","author":"Schell WA","year":"2017","unstructured":"Schell WA, Giamberardino C, Shaw KJ, Perfect JR. 2017. Efficacy of oral APX001 in a murine model of cryptococcal meningitis, poster 1529. Abstr IDWeek 2017, San Diego, CA."},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2015.05.006"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.30.10.1059"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.104.000349"},{"key":"e_1_3_3_31_2","unstructured":"Matsukura M. August 2013. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same. US patent 8513287B2."},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm980539w"},{"key":"e_1_3_3_33_2","unstructured":"Schell WA Giamberardino C Shaw KJ Perfect JR. 2017. IDWeek 2017 poster 1529."},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.11.2.225"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00216-13"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02542-17"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00863-13"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid1001.020779"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.6.1544-1548.2000"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-361"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00126-13"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-015-1023-8"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01181-10"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/bdd.2020"},{"key":"e_1_3_3_45_2","volume-title":"Absorption, distribution, and excretion of [14C]-APX001 after single-dose administration to rats and monkeys, poster 1513","author":"Mansbach RS","year":"2017","unstructured":"Mansbach RS, Shaw KJ, Hodges MR, Coleman S, Fitzsimmons ME. 2017. Absorption, distribution, and excretion of [14C]-APX001 after single-dose administration to rats and monkeys, poster 1513. Abstr IDWeek 2017, San Diego, CA."},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.2165\/11585270-000000000-00000"},{"key":"e_1_3_3_47_2","unstructured":"Tanaka K Inoue S Murai N Matsukura M Nakamoto K Shirotori S Abe S. April 2010. Heterocycles substituted pyridine derivatives and antifungal agent containing thereof. US patent 7 691 882."},{"key":"e_1_3_3_48_2","volume-title":"CLSI document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_49_2","volume-title":"CLSI document M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_3_50_2","volume-title":"Guide for the care and use of laboratory animals","author":"National Research Council","year":"2011","unstructured":"National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.","edition":"8"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00523-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00523-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:23:30Z","timestamp":1645460610000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00523-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1128\/AAC.00523-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.00523-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"2018-03-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-06-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-07-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00523-18"}}